Published in Genome Res on February 01, 2012
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
The use of genomics, proteomics, and metabolomics in identifying biomarkers of male infertility. Fertil Steril (2013) 1.49
Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc Natl Acad Sci U S A (2014) 1.20
Macroscopic stiffness of breast tumors predicts metastasis. Sci Rep (2014) 1.04
Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat Commun (2014) 0.97
Perspectives of integrative cancer genomics in next generation sequencing era. Genomics Inform (2012) 0.94
Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer (2013) 0.93
Current Challenges in Volatile Organic Compounds Analysis as Potential Biomarkers of Cancer. J Biomark (2015) 0.87
SILAC-based quantitative proteomic analysis of gastric cancer secretome. Proteomics Clin Appl (2013) 0.87
pHLIP-FIRE, a cell insertion-triggered fluorescent probe for imaging tumors demonstrates targeted cargo delivery in vivo. ACS Chem Biol (2014) 0.86
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Front Oncol (2014) 0.85
Managing localized prostate cancer in the era of prostate-specific antigen screening. Cancer (2013) 0.82
An emerging toolkit for targeted cancer therapies. Genome Res (2012) 0.81
Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. BMC Med Genomics (2014) 0.78
Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors. Gene Ther (2015) 0.78
Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr Biol (Camb) (2015) 0.77
In vitro models of cancer stem cells and clinical applications. BMC Cancer (2016) 0.77
Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia. Mediators Inflamm (2015) 0.77
CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer. BMC Cancer (2015) 0.75
Data integration to prioritize drugs using genomics and curated data. BioData Min (2016) 0.75
A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types. Oncotarget (2016) 0.75
Evolution-informed modeling improves outcome prediction for cancers. Evol Appl (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
A perspective on cancer cell metastasis. Science (2011) 13.31
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Computed tomography screening and lung cancer outcomes. JAMA (2007) 8.01
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst (2007) 6.08
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Genomics and drug response. N Engl J Med (2011) 4.35
Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst (2005) 3.73
Screening for breast cancer with mammography. Cochrane Database Syst Rev (2011) 3.66
Screening for prostate cancer--the controversy that refuses to die. N Engl J Med (2009) 3.59
Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat Med (2009) 3.58
Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA (2011) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34
The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med (2009) 2.29
Genomics and the continuum of cancer care. N Engl J Med (2011) 2.26
The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med (2004) 2.16
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat (2011) 2.08
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One (2010) 1.65
Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol (2011) 1.43
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol (2011) 1.36
Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res (2004) 1.32
Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology (2011) 1.16
Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials (2010) 1.11
How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst (1996) 0.78